These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20169039)

  • 1. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
    Gennari L; Merlotti D; Nuti R
    Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
    Gennari L
    Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Peterson GM; Naunton M; Tichelaar LK; Gennari L
    Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
    Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
    Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.
    Maximov PY; Lee TM; Jordan VC
    Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ; Hamilton CJ; Jamal SA
    Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective estrogen receptor modulators: the future in menopausal treatment.
    Palacios S
    Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
    Komm BS; Chines AA
    Maturitas; 2012 Mar; 71(3):221-6. PubMed ID: 22196312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
    Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
    Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis.
    Gennari L; Merlotti D; Stolakis K; Nuti R
    Expert Opin Drug Discov; 2011 Feb; 6(2):205-17. PubMed ID: 22647137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.